Get the Stockscreener App
9.71
2.80%
-0.28
After Hours:
9.65
-0.06
-0.62%
Trevi Therapeutics Inc stock is traded at $9.71, with a volume of 1.44M.
It is down -2.80% in the last 24 hours and up +17.70% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$9.99
Open:
$9.67
24h Volume:
1.44M
Relative Volume:
0.67
Market Cap:
$1.18B
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-33.48
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
-2.41%
1M Performance:
+17.70%
6M Performance:
+74.64%
1Y Performance:
+211.22%
1-Day Range:
$9.31
$9.97
1-Week Range:
$9.30
$10.16
52-Week Range:
$2.36
$10.16
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
9.71 | 1.22B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Initiated | Morgan Stanley | Overweight |
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap DownTime to Sell? - MarketBeat
Should I hold or sell Trevi Therapeutics Inc. stock in 2025July 2025 Volume & Community Consensus Picks - newser.com
Does Trevi Therapeutics Inc. show high probability of reboundTrade Volume Summary & Weekly Stock Breakout Alerts - newser.com
Multi factor analysis applied to Trevi Therapeutics Inc.2025 Price Targets & Weekly High Return Stock Opportunities - newser.com
Is Trevi Therapeutics Inc a good long term investmentMarket Timing Techniques & Insights From Wall Street Professionals - earlytimes.in
Is Trevi Therapeutics Inc. stock bottoming out2025 Volatility Report & Long-Term Growth Stock Strategies - newser.com
How to use Fibonacci retracement on Trevi Therapeutics Inc.2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Published on: 2025-10-10 03:52:14 - newser.com
What MACD and RSI say about Trevi Therapeutics Inc.Trade Entry Report & Long-Term Investment Growth Plans - newser.com
Trevi Therapeutics (NASDAQ:TRVI) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Candlestick signals on Trevi Therapeutics Inc. stock todayJuly 2025 Sentiment & Daily Volume Surge Trade Alerts - newser.com
Trevi Therapeutics announces oral presentation and abstracts at Chest 2025 Annual Meeting - MarketScreener
Trevi Therapeutics Announces Oral Presentation And Abstracts At Chest 2025 Annual Meeting - TradingView
Phase 2b CORAL results: Trevi Therapeutics to present nalbuphine ER Oct 21; RIVER 2a PROs poster - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $21.75 Consensus Target Price from Analysts - Defense World
Trevi Therapeutics, Inc. $TRVI Stock Position Boosted by Farther Finance Advisors LLC - Defense World
Trevi Therapeutics Inc. stock trend forecast2025 Trade Ideas & Low Drawdown Trading Strategies - newser.com
Analyzing net buyer seller activity in Trevi Therapeutics Inc.July 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighHere's What Happened - MarketBeat
Trevi Therapeutics stock hits 52-week high at 9.93 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits 52-week high at 9.93 USD - Investing.com
What analysts say about Trevi Therapeutics Inc stockBearish Engulfing Patterns & Tap Into the Fastest-Growing Companies - earlytimes.in
Will earnings trigger a reversal in Trevi Therapeutics Inc.Recession Risk & High Return Stock Watch Alerts - newser.com
Regression analysis insights on Trevi Therapeutics Inc. performancePortfolio Return Summary & Low Risk Growth Stock Ideas - newser.com
Rhumbline Advisers Buys 10,608 Shares of Trevi Therapeutics, Inc. $TRVI - Defense World
Analyzing recovery setups for Trevi Therapeutics Inc. investorsTrade Performance Summary & Precise Buy Zone Tips - newser.com
Trevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific Debut - Yahoo Finance
Custom watchlist performance reports with Trevi Therapeutics Inc.Swing Trade & Reliable Trade Execution Plans - newser.com
Trading Recap: Will Trevi Therapeutics Inc. outperform tech stocksShort Setup & Smart Investment Allocation Tips - خودرو بانک
How Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025 - Yahoo Finance
Is Trevi Therapeutics Inc. stock entering bullish territoryIPO Watch & Target Return Focused Picks - newser.com
Quarterly Risk: Will Trevi Therapeutics Inc. outperform its industry peersBull Run & AI Optimized Trade Strategies - خودرو بانک
Hedge Fund Moves: Can Trevi Therapeutics Inc continue delivering strong returnsWeekly Stock Summary & Fast Entry Momentum Alerts - خودرو بانک
Long term hold vs stop loss in Trevi Therapeutics Inc.Quarterly Market Review & Fast Gaining Stock Reports - newser.com
Market Recap: Can ProShares Trust ProShares UltraShort Russell2000 grow without dilution2025 Technical Patterns & Safe Capital Growth Stock Tips - khodrobank.com
Market Catalysts: Is Trevi Therapeutics Inc forming a breakout patternPortfolio Gains Report & Fast Moving Stock Trade Plans - khodrobank.com
Combining machine learning predictions for Trevi Therapeutics Inc.Weekly Trade Recap & Low Risk Profit Maximizing Plans - newser.com
Trevi Therapeutics to present two phase 2a River trial posters at ERS Congress 2025 - MarketScreener
Trevi Therapeutics To Present Two Phase 2a River Trial Posters At ERS Congress 2025 - TradingView
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025 - PR Newswire
Will Trevi Therapeutics Inc outperform its industry peers2025 Trading Recap & Long-Term Capital Growth Strategies - khodrobank.com
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 4.6%Here's What Happened - MarketBeat
Siren L.L.C. Trims Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Fred Alger Management LLC Takes Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Gap Down: What is the PEG ratio of Trevi Therapeutics IncJuly 2025 Movers & AI Powered Trade Plan Recommendations - خودرو بانک
Dividend Watch: How much upside does Sintx Technologies Inc. haveMarket Rally & Risk Controlled Stock Pick Alerts - خودرو بانک
Revenue Check: How does Trevi Therapeutics Inc compare to its peersJuly 2025 Review & Risk Managed Investment Entry Signals - خودرو بانک
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):